Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.
about
Therapeutic Implications of Targeting AKT Signaling in MelanomaReactivation of telomerase in cancerHEXIM1 induces differentiation of human pluripotent stem cellsInduction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanismRho protein GTPases and their interactions with NFκB: crossroads of inflammation and matrix biologyP27(Kip1), regulated by glycogen synthase kinase-3β, results in HMBA-induced differentiation of human gastric cancer cells.DEAD-box helicase DP103 defines metastatic potential of human breast cancers.Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells.Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.Phosphoprotein network analysis of white adipose tissues unveils deregulated pathways in response to high-fat diet.RNA helicase DP103 and TAK1: a new connection in cancerHMBA Enhances Prostratin-Induced Activation of Latent HIV-1 via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3 in NF-κB SignalingRap1-mediated nuclear factor-kappaB (NF-κB) activity regulates the paracrine capacity of mesenchymal stem cells in heart repair following infarctionTelomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expressionThe PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.Inhibition of NUCKS Facilitates Corneal Recovery Following Alkali BurnAlectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivoNUCKS: a potential biomarker in cancer and metabolic disease.Analysis of the intricate relationship between chronic inflammation and cancer.LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro.Leucine Zipper Down-regulated in Cancer-1 (LDOC1) interacts with Guanine nucleotide binding protein-like 3-like (GNL3L) to modulate Nuclear Factor-kappa B (NF-κB) signaling during cell proliferation.Quantitative assessment of telomerase components in cancer cell lines.Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.Adenosine triphosphate regulates NADPH oxidase activity leading to hydrogen peroxide production and COX-2/PGE2 expression in A549 cells.NFκB drives TERT promoter reactivation in cancer.CD99/MIC2 Constitutes a Differentiation Antigen of a Human Osteoblast Cell Line.SREBP-1c as a molecular bridge between lipogenesis and cell cycle progression of clear cell renal carcinoma.HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack.Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapyN-Substituted Pyrido-1,4-Oxazin-3-Ones Induce Apoptosis of Hepatocellular Carcinoma Cells by Targeting NF-κB Signaling Pathway
P2860
Q24631438-7374FD5F-53EE-4E46-8D1B-981F6A8A7523Q26769014-42050007-9371-453C-B018-316DEB7723C5Q28535456-C9D22C02-435F-4E8A-BB03-F6D3A244510DQ33432584-28E5F8F4-CE6A-43EB-AA0C-3DA9C055F579Q33802112-4DD7969E-4E6C-4DB9-A80E-D15C2440723EQ33856507-13F042C7-1790-4EAC-8919-3FF91A4AE7A2Q34117601-7AF7E4FC-A894-4F6A-AC4B-E4AEEF9C3AB7Q34283730-A66C8073-CB57-410A-93CE-F475D4978BECQ35741628-CD6994BD-88E6-4718-8D05-B980E3DFF9B3Q35832894-FACBB847-1566-409B-A86B-F84570FDF6E0Q35911227-9F897446-8998-4B4D-995E-89EE6EEF6335Q36635311-72F7D005-8FA4-4F4E-BE29-81E2F5DD589BQ36903098-E4F4C93D-C022-4E35-9019-AAE7A3D05602Q36997903-25008106-32B4-4399-A5BE-E6BD7F400EE1Q37162797-EF51E4D2-E168-4FAB-9A05-60B9459BB28EQ37167471-7C6DF999-7377-4B67-860F-DCAEB388A601Q37395716-00B8D8FF-5647-4347-9CF4-1A0A99AC0D9FQ37506648-CC4E8D92-34CC-4D77-8D91-A2BD48E7EE98Q37595322-E905A4F9-C46C-4376-9ADD-1C3A853C6683Q37739472-0CF153B8-9ACD-43EE-9AC1-1B8938842FCBQ38373920-3B1B027E-DB31-4E19-8133-44866C619FE9Q38458724-9E575DA2-3E36-4F88-B3B8-C5CB1F91238FQ38724134-1EF8702B-BF6E-470D-BFB9-24167F81B9DEQ38739496-16EE1C14-95D8-466C-A60E-5B7ABB141B7BQ38902476-7F03D10C-B5E0-4E43-ACFE-E35B4E0768F2Q39156092-C8653FCE-3EEF-4CE7-BC1B-2F9B8E2905E8Q39317905-29021423-8CF6-455D-9595-81E44E661A72Q42910096-35D61889-BFE8-4DAC-8732-2B2269077DABQ43839408-D532F9B0-69DA-449E-9C7C-79116D89D4F4Q47402308-795878FA-0BC8-4C86-981B-E6D968F09500Q54532891-167526BD-0755-47D0-8F8F-0B1B13E727B8Q57044361-536DB5FD-4D7F-47CC-8A42-7532B331AF7AQ59130161-706C3BF4-A911-4F43-A2B1-EC7B29EAC576
P2860
Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Hexamethylene bisacetamide (HM ...... plications for cancer therapy.
@en
Hexamethylene bisacetamide
@nl
type
label
Hexamethylene bisacetamide (HM ...... plications for cancer therapy.
@en
Hexamethylene bisacetamide
@nl
prefLabel
Hexamethylene bisacetamide (HM ...... plications for cancer therapy.
@en
Hexamethylene bisacetamide
@nl
P2093
P356
P1433
P1476
Hexamethylene bisacetamide (HM ...... mplications for cancer therapy
@en
P2093
Anwesha Dey
Eetsin Wong
Hsiang Ling Teo
Vinay Tergaonkar
P304
P356
10.4161/CC.7.23.7213
P50
P577
2008-12-10T00:00:00Z